Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SIGYC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TTZ-Mc-NPV-MMAE
|
|||||
| Synonyms |
TTZ MC NPV MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Asn-Pro-Val-PABC
|
Linker Info | ||||
| Conjugate Type |
The conjugation of the linker on trastuzumab was realized, by a site-specific conjugation method, using a (diphenylthiomaleimido)caproic acid (diSPhMC) head for disulfide stapling on cysteine residues. .
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.